LSE - Delayed Quote EUR

Sanofi (0O59.L)

97.31

+0.09

+(0.09%)

At close: July 25 at 8:02:04 AM GMT+1

Press Release: Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs

Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs Late-breaking data show infant respiratory syncytial virus (RSV) hospitalizations reduced by 69% in Spain following Beyfortus-only immunization targeted to all infants and 26.7% in the UK following RSVpreF-only maternal vaccination Newly presented durability data show Beyfortus sustained efficacy of 83% through six months in babies born before or during the RSV season Paris,

GlobeNewswire 8 hours ago

SNY

SNYNF
Sanofi: New Anthem from Girl Band Raises Awareness of Type 1 Diabetes After Research Highlights Silent Struggle

Today, Sanofi and Stagecoach Performing Arts are excited to introduce a unique partnership. Selected through a UK-wide audition process, four talented teens living with autoimmune Type 1 diabetes (aT1D) have come together to form a girl band named "1Type". In response to new research highlighting the significant impact of aT1D on those living with the condition[1] the group has released an original song called "Rise Up" to empower young people living with aT1D and help them feel less alone.

PR Newswire 13 hours ago

SNY

SNYNF
Press Release: Sanofi completes acquisition of DR-0201

Sanofi completes acquisition of DR-0201 Paris, May 27, 2025. Sanofi announces the completion of its acquisition of DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio, Inc., a private clinical-stage biopharmaceutical company. The acquisition bolsters Sanofi’s ambition to become the foremost immunology company and broadens the company’s leading immunology pipeline. DR-0201, now named SAR448501, has shown robust B-cell depletion in pre-clinical and early clinical studies. The potent

GlobeNewswire 2 days ago

SNY

SNYNF
Vigil Neuroscience to be acquired by Sanofi for $8.00 per share

Vigil Neuroscience (VIGL) and Sanofi (SNY) announced that it has entered into a definitive merger agreement pursuant to which Sanofi will acquire Vigil for an upfront payment of $8.00 per share of common stock in cash. Vigil shareholders will also receive a non-tradeable contingent value right entitling the holder to potentially receive an additional $2.00 per share in cash payable following the first commercial sale of VG-3927 if achieved within a specific period. The total equity value of the

TipRanks 6 days ago

SNY

SNYNF

VIGL
Sanofi opens new, $130 million NJ offices in Morristown, showcasing innovative, modern design and strengthening US presence

Sanofi today announces the formal opening of the company's new flagship US offices, unveiling a state-of-the-art modern workplace fostering collaboration and innovation with the ultimate goal of bringing medicines and vaccines to patients faster.

PR Newswire 6 days ago

SNY

SNYNF
Sanofi Inks A $470 Million Alzheimer's Deal, Sending This Dollar Stock Flying

Vigil Neuroscience tripled Thursday after Sanofi agreed to buy it for $470 million plus a CVR tied to its experimental Alzheimer's treatment.

Investor's Business Daily 7 days ago

SNY

SNYNF

AMGN
Sanofi to Buy Vigil Neuroscience for About $470 Million

Sanofi has entered an agreement to acquire Vigil Neuroscience for approximately $470 million, adding a new investigational treatment for Alzheimer’s disease to the French pharmaceutical company’s pipeline.

The Wall Street Journal 7 days ago

VIGL

SNY

SNYNF
Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi

- Vigil’s shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale of VG-3927 - - Acquisition expected to strengthen development path for the oral small molecule TREM2 agonist program, including VG-3927, a Phase 2-ready clinical candidate for potential treatment of Alzheimer’s disease – - Companies expect transaction to close in third quarter of

GlobeNewswire 7 days ago

VIGL

SNY

SNYNF
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline Paris, May 22, 2025. Sanofi announced today that it has entered into an agreement to acquire Vigil Neuroscience, Inc. (“Vigil”), a publicly traded clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases. This acquisition in neurology, one of Sanofi’s four strategic disease areas, enhances Sanofi’s early-stage pi

GlobeNewswire 7 days ago

SNY

SNYNF
Sanofi (ENXTPA:SAN) Partners With Viz.ai To Enhance AI Solutions For COPD Management

Sanofi (ENXTPA:SAN) recently entered into a multi-year partnership with Viz.ai and Regeneron to develop an AI-powered solution for COPD management, reflecting its focus on innovation. Over the last month, the company’s stock increased by 1.71%, paralleling broader market trends, which have seen modest gains amid easing trade concerns and strong corporate earnings. This stock movement coincides with Sanofi's robust Q1 earnings growth and a significant share buyback completion. The company’s...

Simply Wall St. 9 days ago

SNY

SNYNF
Sanofi: Information concerning the total number of voting rights and shares - April 2025

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,452,461,656Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Regis

GlobeNewswire 14 days ago

SNY

SNYNF
Sanofi to invest at least $20 billion in the US through 2030, growing investments in science and expanding domestic manufacturing

Sanofi today announces its intention to invest at least $20 billion in the United States through 2030. The expected investment includes a significant increase in research and development spending and the allocation of billions of dollars to US manufacturing.

PR Newswire 15 days ago

SNY

SNYNF
Trump’s Vow to Cut US Drug Prices Drags Pharma Stocks Lower

(Bloomberg) -- President Donald Trump said he plans to order a cut in US prescription drug costs to bring them in line with other countries, spurring a drop in pharmaceutical shares worldwide.Most Read from BloombergA New Central Park Amenity, Tailored to Its East Harlem NeighborsAs Trump Reshapes Housing Policy, Renters Face Rollback of RightsWhat’s Behind the Rise in Serious Injuries on New York City’s Streets?NYC Warns of 17% Drop in Foreign Tourists Due to Trump PoliciesLA Mayor Credits Trum

Bloomberg 17 days ago

AZN

AZNCF

BERZ
Pharmaceutical Stocks Tumble on Trump Plan to Cut US Drug Prices

(Bloomberg) -- Shares of pharmaceutical companies fell across the world after US President Donald Trump said he planned to order a cut in US prescription drug costs to bring them in line with other countries, prompting concern that profits will take a hit.Most Read from BloombergA New Central Park Amenity, Tailored to Its East Harlem NeighborsAs Trump Reshapes Housing Policy, Renters Face Rollback of RightsWhat’s Behind the Rise in Serious Injuries on New York City’s Streets?Is Trump’s Plan to R

Bloomberg 17 days ago

C

TAK

TKPHF
European Firms Fare Better Than Feared Through Early Trade Pain

(Bloomberg) -- European firms are reporting earnings significantly ahead of expectations, allowing for some relief in the market, but tariffs and the uncertain path of economic growth continue to cloud the outlook.Most Read from BloombergThe Battle Over the Fate of Detroit’s Renaissance CenterNYC Real Estate Industry Asks Judge to Block New Broker Fee LawNJ Transit Strike Would Be ‘Disaster’ for Region, Sherrill SaysIceland Plans for a More Volcanic FutureNJ Transit Urges Commuters to Work Remot

Bloomberg 24 days ago

SNY

SNYNF

SCGLF
Sanofi: Information concerning the total number of voting rights and shares - March 2025

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,452,461,656Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Regis

GlobeNewswire 27 days ago

SNY

SNYNF
Sanofi (ENXTPA:SAN) Announces €4 Per Share Dividend And New Compensation Committee Chair

Sanofi (ENXTPA:SAN) saw a 2.85% increase in its share price last week, coinciding with notable company updates. The pharmaceutical giant announced a dividend increase to €3.92 per share during its Annual General Meeting, likely reinforcing investor confidence. Additionally, Clotilde Delbos' appointment as Chairwoman of the Compensation Committee underscores a strategic personnel change. While the market also rose by 2.7%, Sanofi's earnings boost and dividend announcement may have added...

Simply Wall St. 28 days ago

SNY

SNYNF
Press Release: Annual General Meeting of April 30, 2025

Annual General Meeting of April 30, 2025 Approval of the financial statements for the fiscal year 2024Distribution of a cash dividend of €3.92 per share, with payment as of May 14, 2025Board composition: renewal of four Directors and ratification of the cooptation of Jean-Paul Kress Paris, April 30, 2025. The Combined General Shareholders’ Meeting of Sanofi was held on April 30, 2025, under the chairmanship of Frédéric Oudéa. All resolutions submitted to the vote were adopted by the shareholders

GlobeNewswire 29 days ago

SNY

SNYNF
Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader

Sanofi and CD&R close Opella transaction, create global consumer healthcare leader Paris, April 30, 2025. Opella today becomes an independent global leader in consumer healthcare, marking a pivotal step in Sanofi's strategy. Sanofi announces today the closing of the sale to CD&R of a 50.0% controlling stake of its consumer healthcare business Opella. Sanofi retains a significant shareholding of Opella with a 48.2% stake. Bpifrance will own a 1.8% stake in Opella and will join the Board. The tran

GlobeNewswire 29 days ago

SNY

SNYNF
Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race

When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race Paris, April 29, 2025. Sanofi is proud to unveil an exciting new chapter in its mission to fight meningitis, as it expands its partnership with McLaren Racing for a powerful activation alongside United Autosports, the official racing partner of McLaren Automotive. This unique collaboration will see the Meningitis Flag — a powerful symbol of the global fight ag

GlobeNewswire 30 days ago

SNY

SNYNF

Performance Overview

Return	0O59.L	MSCI WORLD (^990100-USD-STRD)
YTD	+8.92%	+4.17%
1-Year	+14.14%	+12.60%
3-Year	+7.17%	--

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Sanofi (0O59.L)

Press Release: Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs

Sanofi: New Anthem from Girl Band Raises Awareness of Type 1 Diabetes After Research Highlights Silent Struggle

Press Release: Sanofi completes acquisition of DR-0201

Vigil Neuroscience to be acquired by Sanofi for $8.00 per share

Sanofi opens new, $130 million NJ offices in Morristown, showcasing innovative, modern design and strengthening US presence

Sanofi Inks A $470 Million Alzheimer's Deal, Sending This Dollar Stock Flying

Sanofi to Buy Vigil Neuroscience for About $470 Million

Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi

Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline

Sanofi (ENXTPA:SAN) Partners With Viz.ai To Enhance AI Solutions For COPD Management

Sanofi: Information concerning the total number of voting rights and shares - April 2025

Sanofi to invest at least $20 billion in the US through 2030, growing investments in science and expanding domestic manufacturing

Trump’s Vow to Cut US Drug Prices Drags Pharma Stocks Lower

Pharmaceutical Stocks Tumble on Trump Plan to Cut US Drug Prices

European Firms Fare Better Than Feared Through Early Trade Pain

Sanofi: Information concerning the total number of voting rights and shares - March 2025

Sanofi (ENXTPA:SAN) Announces €4 Per Share Dividend And New Compensation Committee Chair

Press Release: Annual General Meeting of April 30, 2025

Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader

Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race

Performance Overview